收稿日期: 2022-06-12
网络出版日期: 2022-10-14
周德敏 , 李海伟 , 肖苏龙 . 中药抗病毒的物质基础：从五环三萜说开来[J]. 北京大学学报（医学版）, 2022 , 54(5) : 832 -836 . DOI: 10.19723/j.issn.1671-167X.2022.05.009
| 1 | Ruzicka L . The isoprene rule and the biogenesis of terpenic compounds[J]. Experientia, 1953, 9 (10): 357- 367. |
| 2 | Joshi RK . Role of natural products against microorganisms[J]. Am J Clin Microbiol Antimicrob, 2018, 1 (1): 1005. |
| 3 | Papadopoulou K , Melton RE , Leggett M , et al. Compromised disease resistance in saponin-deficient plants[J]. Proc Natl Acad Sci USA, 1999, 96 (22): 12923- 12928. |
| 4 | Si L , Meng K , Tian Z , et al. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes[J]. Sci Adv, 2018, 4 (11): eaau8408. |
| 5 | Yu M , Si L , Wang Y , et al. Discovery of pentacyclic triterpenoids as potential entry inhibitors of influenza viruses[J]. J Med Chem, 2014, 57 (23): 10058- 10071. |
| 6 | Yu F , Wang Q , Zhang Z , et al. Development of oleanane-type triterpenes as a new class of HCV entry inhibitors[J]. J Med Chem, 2013, 56 (11): 4300- 4319. |
| 7 | Li H , Wang S , Ma W , et al. Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders[J]. J Med Chem, 2022, 65 (10): 7154- 7169. |
| 8 | DeJesus E , Harward S , Jewell RC , et al. A phase Ⅱ a study evaluating safety, pharmacokinetics, and antiviral activity of GSK2838232, a novel, second-generation maturation inhibitor, in participants with human immunodeficiency virus type 1 infection[J]. Clin Infect Dis, 2020, 71 (5): 1255- 1262. |
| 9 | Margot NA , Gibbs CS , Miller MD . Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat[J]. Antimicrob Agents Chemother, 2010, 54 (6): 2345- 2353. |
| 10 | Vigant F , Santos NC , Lee B . Broad-spectrum antivirals against viral fusion[J]. Nat Rev Microbiol, 2015, 13 (7): 426- 437. |
| 11 | Harrison SC . Viral membrane fusion[J]. Nat Struct Mol Biol, 2008, 15 (7): 690- 698. |
| 12 | Rennie ML , Chaugule VK , Walden H . Modes of allosteric regulation of the ubiquitination machinery[J]. Curr Opin Struct Biol, 2020, 62, 189- 196. |
| 13 | Weissenhorn W , Hinz A , Gaudin Y . Virus membrane fusion[J]. FEBS Lett, 2007, 581 (11): 2150- 2155. |
| 14 | Russell RJ , Gamblin SJ , Haire LF , et al. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes[J]. Virology, 2004, 325 (2): 287- 296. |
| 15 | Bressanelli S , Stiasny K , Allison SL , et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation[J]. Embo J, 2004, 23 (4): 728- 738. |
| 16 | Fujioka T , Kashiwada Y , Kilkuskie RE , et al. Anti-AIDS agents, 11. betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids[J]. J Nat Prod, 1994, 57 (2): 243- 247. |
| 17 | Evers M , Poujade C , Soler F , et al. Betulinic acid derivatives: a new class of human immunodeficiency virus type 1 specific inhibitors with a new mode of action[J]. J Med Chem, 1996, 39 (5): 1056- 1068. |
| 18 | Kashiwada Y , Hashimoto F , Cosentino LM , et al. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents[J]. J Med Chem, 1996, 39 (5): 1016- 1017. |
| 19 | Mayaux JF , Bousseau A , Pauwels R , et al. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells[J]. Proc Natl Acad Sci USA, 1994, 91 (9): 3564- 3568. |
| 20 | Dang Z , Lai W , Qian K , et al. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors[J]. J Med Chem, 2009, 52 (23): 7887- 7891. |
| 21 | Soler F , Poujade C , Evers M , et al. Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry[J]. J Med Chem, 1996, 39 (5): 1069- 1083. |
| 22 | Yang JP , Zhou D , Wong-Staal F . Screening of small-molecule compounds as inhibitors of HCV entry[J]. Methods Mol Biol, 2009, 510, 295- 304. |
| 23 | C?té M , Misasi J , Ren T , et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection[J]. Nature, 2011, 477 (7364): 344- 348. |
| 24 | Hu Y , Lu S , Song Z , et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance[J]. Lancet, 2013, 381 (9885): 2273- 2279. |
| 25 | Takashita E . Influenza polymerase inhibitors: mechanisms of action and resistance[J]. Cold Spring Harb Perspect Med, 2021, 11 (5): a038687. |
| 26 | Burslem GM , Crews CM . Proteolysis-targeting chimeras as therapeutics and tools for biological discovery[J]. Cell, 2020, 181 (1): 102- 114. |
| 27 | Chamberlain PP , Hamann LG . Development of targeted protein degradation therapeutics[J]. Nat Chem Biol, 2019, 15 (10): 937- 944. |
| 28 | Bushweller JH . Targeting transcription factors in cancer: from undruggable to reality[J]. Nat Rev Cancer, 2019, 19 (11): 611- 624. |
| 29 | Li F , Goila-Gaur R , Salzwedel K , et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing[J]. Proc Natl Acad Sci USA, 2003, 100 (23): 13555- 13560. |
| 30 | Purdy MD , Shi D , Chrustowicz J , et al. MicroED structures of HIV-1 Gag CTD-SP1 reveal binding interactions with the maturation inhibitor bevi-rimat[J]. Proc Natl Acad Sci USA, 2018, 115 (52): 13258- 13263. |
| 31 | Jacob J, Richards J, Augustine J, et al. Liquid bevirimat dosage forms for oral administration: WO2009042166A1[P/OL]. 2010-08-26[2022-08-20]. https://patents.google.com/patent/WO2009042166A1/en?oq=WO2009042166A1. |
| 32 | Liu Z , Swidorski JJ , Nowicka-Sans B , et al. C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors[J]. Bioorg Med Chem, 2016, 24 (8): 1757- 1770. |
| 33 | Swidorski JJ , Liu Z , Sit SY , et al. Inhibitors of HIV-1 maturation: development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids[J]. Bioorg Med Chem Lett, 2016, 26 (8): 1925- 1930. |
| 34 | Regueiro-Ren A , Dicker IB , Hanumegowda U , et al. Second generation inhibitors of HIV-1 maturation[J]. ACS Med Chem Lett, 2019, 10 (3): 287- 294. |
| 35 | Regueiro-Ren A , Liu Z , Chen Y , et al. Discovery of BMS-955176, a second generation HIV-1 maturation inhibitor with broad spectrum antiviral activity[J]. ACS Med Chem Lett, 2016, 7 (6): 568- 572. |
| 36 | Hwang C , Schürmann D , Sobotha C , et al. Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)[J]. Clin Infect Dis, 2017, 65 (3): 442- 452. |
/
| 〈 |
|
〉 |
